Phase 3 study for people with Huntington's Disease

By invitation Phase 3

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status By invitation
Phase Phase 3
Sponsor Skyhawk Therapeutics, Inc.
Registry number NCT07537075
Started 10 April 2026 Today 16 October 2026 Estimated completion 1 December 2029

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
John Hunter Hospital New Lambton Heights NSW Status not stated
Westmead Hospital Westmead NSW Status not stated
The University of Queensland Herston QLD Status not stated
Flinders Medical Centre Adelaide SA Status not stated
Calvary Health Care Bethlehem Caulfield South VIC Status not stated
The Royal Melbourne Hospital Parkville VIC Status not stated
The Perron Institute for Neurology and Translational Science (Perron Institute) Nedlands WA Status not stated

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 25 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 500

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Must have completed treatment in a prior SKY-0515 treatment study and, in the opinion of the Investigator, have been compliant with the prior SKY-0515 treatment protocol study procedures.

* Must be able and willing to meet all study requirements in the opinion of the Investigator including:

* Participants must be able to tolerate blood draws

* Willing and able to comply with all scheduled visits, treatment plans,laboratory tests and other study procedures

* Women who can have children must have a negative pregnancy test before starting and use two types of birth control during the study and for 30 days after the last dose of the study drug.

* Men must agree to use birth control during the study and for 90 days after the last dose.

Exclusion Criteria:

-Have any other conditions that, in the opinion of the Investigator or Sponsor, would make the participant unsuitable for inclusion, or could interfere with the participant participating in or completing the study.

Dates on the record

Started 10 April 2026
Estimated completion 1 December 2029
Registry last updated 24 July 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 24 July 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.